2020
DOI: 10.1101/2020.07.01.182402
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Isomerization of antimalarial drug WR99210 explains its inactivity in a commercial stock

Abstract: ABSTRACTWR99210, a former antimalarial drug candidate now widely used for the selection of Plasmodium transfectants, selectively targets the parasite dihydrofolate reductase thymidine synthase bifunctional enzyme (DHFR-TS) but not human DHFR, which is not fused with TS. Accordingly, WR99210 and plasmids expressing human dhfr have become valued tools for the genetic modification of parasites in the laboratory. Concerns over t… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 27 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?